Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LVSNV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
vH4Vk3-CL2A-SN38 ADC
|
|||||
| Synonyms |
VH4Vk3-CL2A-SN38 ADC
Click to Show/Hide
|
|||||
| Organization |
Mbarase Treatment Co; University Medicine And Dentistry New Jersey Medical School
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
VH4Vk3
|
Antibody Info | ||||
| Antigen Name |
Ephrin type-A receptor 5 (EPHA5)
|
Antigen Info | ||||
| Payload Name |
Active metabolite of irinotecan SN38
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
CL2A
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
CL2A-SN38
|
|||||